Addex drug-candidate effective in Alzheimer's disease model
Addex Pharmaceuticals Ltd announced that it has observed efficacy in a model of Alzheimer's disease using a recently discovered orally-available drug-candidate. The proprietary molecule specifically inhibits a receptor subtype called the metabotropic glutamate receptor 2 (mGluR2) via negative allosteric modulation (NAM). An Addex mGluR2 NAM is scheduled to enter Phase I clinical testing in healthy volunteers ... more
Epistem Announce Agency Agreement With Veritas Japan
Epistem plc announced that its Contract Research Services division has entered into an agreement with the Veritas Corporation to exclusively market and distribute Epistem's scientific research services in Japan. The Veritas agreement will provide Epistem with a sales and marketing presence in Japan and the opportunity to extend its research services, and respond rapidly to market demand.Epistem's CEO Matthew ... more
Top